Chemours (NYSE:CC) Stock Price Target Cut by UBS Group

Chemours (NYSE:CC) had its target price lowered by analysts at UBS Group from $16.00 to $15.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the specialty chemicals company’s stock. UBS Group‘s price target would indicate a potential upside of 9.00% from the stock’s previous close.

CC has been the subject of several other reports. Mizuho cut shares of Chemours from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $18.00 to $15.00 in a research report on Wednesday, October 14th. Royal Bank Of Canada lowered shares of Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price target on the stock. in a report on Tuesday, October 13th. Zacks Research raised shares of Chemours from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 10th. Truist Financial decreased their price objective on Chemours from $20.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday. Finally, BMO Capital Markets decreased their price objective on Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a report on Thursday, August 13th. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Chemours currently has an average rating of “Hold” and an average price target of $17.45.

Chemours Price Performance

CC traded up $0.67 on Wednesday, reaching $13.76. The stock had a trading volume of 4,007,061 shares, compared to its average volume of 2,817,230. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of -13.49 and a beta of 1.47. Chemours has a fifty-two week low of $10.44 and a fifty-two week high of $28.67. The firm has a 50-day moving average of $14.12 and a 200-day moving average of $18.25.

Chemours (NYSE:CC) last announced its quarterly earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). The firm had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.53 billion. Chemours had a negative net margin of 2.64% and a positive return on equity of 78.76%. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.40 earnings per share. As a group, sell-side analysts anticipate that Chemours will post 0.83 EPS for the current year.

Insider Activity

In other news, CFO Shane Hostetter acquired 3,350 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was bought at an average cost of $14.94 per share, for a total transaction of $50,049.00. Following the completion of the transaction, the chief financial officer directly owned 102,698 shares in the company, valued at $1,534,308.12. This represents a 3.37% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Denise Dignam bought 3,378 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were purchased at an average cost of $14.95 per share, with a total value of $50,501.10. Following the purchase, the chief executive officer directly owned 339,916 shares of the company’s stock, valued at $5,081,744.20. The trade was a 1.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 8,663 shares of company stock valued at $130,601. 0.85% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CC. BlackRock Inc. bought a new position in Chemours in the second quarter worth approximately $477,769,000. Wolf Hill Capital Management LP bought a new stake in shares of Chemours during the second quarter valued at approximately $59,698,056. Bank of New York Mellon Corp bought a new stake in shares of Chemours during the second quarter valued at approximately $33,353,000. Legal & General Group Plc bought a new position in shares of Chemours in the 2nd quarter worth $28,400,000. Finally, Bank of America Corp DE lifted its holdings in shares of Chemours by 79.1% in the 1st quarter. Bank of America Corp DE now owns 1,317,003 shares of the specialty chemicals company’s stock worth $29,014,000 after purchasing an additional 581,621 shares in the last quarter. 76.26% of the stock is owned by institutional investors.

Key Stories Impacting Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon, a two-phase liquid-cooling solution targeting AI data centers, opening a potential growth avenue in a rapidly expanding market. Article: Chemours launches Faizeon cooling solutions
• Positive Sentiment: Fourth-quarter 2026 revenue guidance of $1.7 billion–$1.8 billion is above the cited $1.4 billion consensus. Full-year revenue guidance of $5.9 billion is in line with estimates. Article: Chemours provides earnings guidance
• Positive Sentiment: Truist lowered its price target to $18 from $20 but kept a Buy rating, indicating it still sees upside from the cited share price. Article: Truist price-target update
• Neutral Sentiment: UBS cut its target to $15 from $16 and maintained a Neutral rating, reflecting a more guarded outlook. Article: UBS adjusts Chemours price target
• Negative Sentiment: Third-quarter adjusted EPS of $0.21 missed the $0.26 consensus. Analysts also cited weak volumes and a cautious fourth-quarter outlook, keeping concerns about underlying demand in focus despite the revenue guidance. Article: Q3 results and outlook
• Negative Sentiment: Several law firms publicized a securities class action filed on behalf of investors who bought shares from February 20 to August 4, 2026. The suit alleges Chemours misrepresented Opteon refrigerant aftermarket demand, including distributor inventory timing; these claims are allegations, not established findings. The lead-plaintiff deadline is December 7, 2026, adding potential legal and reputational risk. Article: Chemours class-action reminder

About Chemours

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.